Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company
By Dr. Matthew Watson
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to the U.S. House of Representatives on illegal market manipulation of the common stock of Scilex.
Related Post
- Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT - June 10th, 2024
- Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting - June 10th, 2024
- Nusano Names D. Scott Holbrook as Chairman of its Board - June 10th, 2024
- TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - June 10th, 2024
- Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained... - June 10th, 2024
- Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - June 10th, 2024
- Epic Bio to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress - June 10th, 2024
- PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024 - June 10th, 2024
- Octane Medical acquires B. Braun’s global orthobiologics business - June 10th, 2024
- CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for... - June 10th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 10th, 2024
- Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 - June 10th, 2024
- Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the... - June 10th, 2024
- Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders - June 10th, 2024
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of... - June 10th, 2024
- 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease... - June 10th, 2024
- European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer - June 10th, 2024
- Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing - June 10th, 2024
- Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix - June 10th, 2024
- Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization - June 10th, 2024
- Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency - June 2nd, 2024
- DBV Technologies Announces Plan to Implement ADS Ratio Change - June 2nd, 2024
- Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase... - June 2nd, 2024
- Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine - June 2nd, 2024
- Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine - June 2nd, 2024
- AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing... - June 2nd, 2024
- Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib - June 2nd, 2024
- Mainz Biomed Reports Results of 2024 Annual General Meeting - June 2nd, 2024
- CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting - June 2nd, 2024
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous... - June 2nd, 2024
- Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting - June 2nd, 2024
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical... - June 2nd, 2024
- Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - June 2nd, 2024
- Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid... - June 2nd, 2024
- Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting - June 2nd, 2024
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - June 2nd, 2024
- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical... - June 2nd, 2024
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in... - June 2nd, 2024
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in... - June 2nd, 2024
- Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive... - June 2nd, 2024
- Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 - May 25th, 2024
- Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications - May 25th, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid... - May 25th, 2024
- Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - May 25th, 2024
- Minutes of Annual General Meeting 2024 - May 25th, 2024
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 25th, 2024
- Monopar Announces CFO Succession - May 25th, 2024
- Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 25th, 2024
- IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - May 25th, 2024
- BioSenic provides First Quarter 2024 Business Update - May 25th, 2024
- Purespring Therapeutics presents preclinical data at the 61st ERA Congress - May 25th, 2024
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - May 25th, 2024
- Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome - May 25th, 2024
- Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - May 25th, 2024
- Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. - May 25th, 2024
- OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - May 25th, 2024
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events - May 25th, 2024
- Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - May 25th, 2024
- Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting - May 25th, 2024
- Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy... - May 17th, 2024
- Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer - May 17th, 2024
- Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 - May 17th, 2024
- Assertio to Participate in AGP Healthcare Conference on May 21 - May 17th, 2024
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - May 17th, 2024
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives - May 17th, 2024
- Digital Utilities Ventures Completes Feed Earth Now Merger - Accelerates Growth of Regenerative Agriculture Movement - May 17th, 2024
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - May 17th, 2024
- Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - May 17th, 2024
- Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference - May 17th, 2024
- New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with... - May 17th, 2024
- Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference - May 17th, 2024
- BioSyent Releases Financial Results for Q1 2024 - May 17th, 2024
- BioSyent Declares Second Quarter 2024 Dividend - May 17th, 2024
- Lifecore Biomedical Completes Incremental Liquidity Initiatives - May 17th, 2024
- DBV Technologies Announces Results of its 2024 Combined General Meeting - May 17th, 2024
- Fortrea Appoints Machelle Sanders to Board of Directors - May 17th, 2024
- QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 17th, 2024
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 17th, 2024
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 17th, 2024
- Telesis Bio Announces Reverse Stock Split - May 7th, 2024
Global News Feed
Comments Off on Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company |
May 25th, 2024
This author published 5592 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research